SAREPTA THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
SAREPTA THERAPEUTICS, INC. (SRPT) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2024-02-28
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-09-30 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-06-30 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-03-31 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2022-09-30 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2022 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2021 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2020 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-28 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2023-11-01 | 0.00 shares 10-Q · filed 2023-11-01 | ||
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-08-02 | 0.00 shares 10-Q · filed 2023-08-02 | ||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2024-02-28 | |||
| 2022-09-30 | 0.00 shares 10-Q · filed 2023-11-01 | 0.00 shares 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | 0.00 shares 10-Q · filed 2023-08-02 | 0.00 shares 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2024-02-28 | |||
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-02 | 0.00 shares 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-02 | 0.00 shares 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | 0.00 shares 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | 0.00 shares 10-K · filed 2023-02-28 | |||
| 2020-09-30 | 0.00 shares 10-Q · filed 2021-11-03 | 0.00 shares 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | 0.00 shares 10-Q · filed 2021-08-04 | 0.00 shares 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | 0.00 shares 10-K · filed 2022-03-01 | |||
| 2019-09-30 | 0.00 shares 10-Q · filed 2020-11-05 | 0.00 shares 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | 0.00 shares 10-Q · filed 2020-08-05 | 0.00 shares 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | 0.00 shares 10-K · filed 2021-03-01 | |||
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-07 | 0.00 shares 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | 0.00 shares 10-Q · filed 2019-08-07 | 0.00 shares 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-02-28 | |||
| 2017-09-30 | 0.00 shares 10-Q · filed 2018-10-31 | 0.00 shares 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | 0.00 shares 10-Q · filed 2018-08-08 | 1.26M shares 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | 1.16M shares 10-Q · filed 2018-05-03 | |||
| 2016-12-31 | 0.00 shares 10-K · filed 2019-02-28 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-01 | 0.00 shares 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2017-08-03 | 0.00 shares 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | 0.00 shares 10-Q · filed 2017-05-04 | |||
| 2015-12-31 | 0.00 shares 10-K · filed 2018-03-01 | |||
| 2015-09-30 | 0.00 shares 10-Q · filed 2016-11-07 | 0.00 shares 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-09 | 0.00 shares 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-02-28 | |||
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-08-06 | 0.00 shares 10-Q · filed 2015-08-06 | ||
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-02-25 | |||
| 2013-06-30 | 0.00 shares 10-Q · filed 2014-08-07 | 0.00 shares 10-Q · filed 2014-08-07 | ||
| 2012-12-31 | 0.00 shares 10-K · filed 2015-02-26 | |||
| 2012-06-30 | 34.00K shares 10-Q · filed 2013-08-08 | |||
| 2011-12-31 | 0.00 shares 10-K · filed 2013-03-15 | |||
| 2011-06-30 | 805.00K shares 10-Q · filed 2012-08-07 | 1.11M shares 10-Q · filed 2012-08-07 | ||
| 2010-12-31 | 0.00 shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |